Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.
BACKGROUND
HMGCR(3-Hydroxy-3-methylglutaryl coenzyme A reductase), the direct target of statin inhibition, undergoes alternative splicing of exon 13, which encodes part of the statin-binding domain of the enzyme. We hypothesized that HMGCR alternative splicing might be related to the interindividual variation in plasma low-density lipoprotein cholesterol response to statin treatment.


RESULTS
We measured mRNA expression of both the full-length and the alternatively spliced HMGCR transcript lacking exon 13 (HMGCRv_1) in 170 simvastatin-incubated immortalized lymphocyte cell lines derived from participants in the Cholesterol and Pharmacogenetics (CAP) study who were treated with simvastatin 40 mg/d for 6 weeks. Greater upregulation of HMGCRv_1 in vitro was significantly correlated (P<or=0.0001) with smaller in vivo reductions of plasma total cholesterol, low-density lipoprotein cholesterol, apoprotein B, and triglycerides and explained 6% to 15% of the variation in their response to treatment. In contrast, no significant relationship was found between expression of the full-length HMGCR transcript and in vivo response. By siRNA knockdown of the full-length transcript, we found that HMGCR enzyme activity measured in cells enriched in HMGCRv_1 was relatively resistant to statin inhibition, consistent with the association of increased alternative splicing with reduced statin response in the CAP study. In addition, we found that a common HMGCR single-nucleotide polymorphism (rs3846662) located within intron 13 was associated with variation in the proportion of HMGCR mRNA that is alternatively spliced.


CONCLUSIONS
Variation in the production of an HMGCR isoform with reduced statin sensitivity is a determinant of interindividual differences in low-density lipoprotein cholesterol, apolipoprotein B, and triglyceride response to statin treatment.
Children's Hospital Oakland Research Institute, CA 94609, USA.
Marisa Wong
MW
Medina
Feng
F
Gao
Weiming
W
Ruan
Jerome I
JI
Rotter
Ronald M
RM
Krauss
D000328:Adult; D017398:Alternative Splicing / Q000502:physiology*; D001055:Apolipoproteins B / Q000097:blood; D044383:Black People; D002460:Cell Line; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects*; D005260:Female; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000235:genetics* / Q000502:physiology; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects; D008297:Male; D010349:Patient Compliance; D020641:Polymorphism, Single Nucleotide; D012333:RNA, Messenger / Q000032:analysis; D019821:Simvastatin / Q000008:administration & dosage / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood; D015854:Up-Regulation; D044465:White People
D001055:Apolipoproteins B; D008078:Cholesterol, LDL; D012333:RNA, Messenger; D014280:Triglycerides; D019821:Simvastatin; D006903:Hydroxymethylglutaryl CoA Reductases